TROP‐2 expression in papillary thyroid carcinoma

Abstract

TROP-2 is a type I transmembrane glycoprotein which is over-expressed in various malignancies, and is related to epithelial cell adhesion molecule (EpCAM), also called TROP-1, gp40, and KSA. In this study, we evaluated TROP-2 expression in papillary thyroid carcinoma (PTC) and compared it to other thyroid neoplastic and non-neoplastic lesions. Immunohistochemical (IHC) evaluation for TROP-2 was performed on 137 thyroid fine needle aspiration (FNA) cell blocks (CB) which included classic PTC (64), follicular variant PTC (FVPTC) (10), anaplastic thyroid carcinoma (AC) (2), medullary carcinoma (MC) (8), follicular neoplasms (FN) (8), Hurthle cell neoplasms (HCN) (9), follicular lesion of uncertain significance (FLUS) (12), and benign thyroid nodule (BTN) (24). IHC for TROP-2 expression was also performed on 331 BTN and malignant tumor tissue sections in tissue microarray (TMA). Membranous staining in >5% of tumor cells was considered positive. TROP-2 stained 61 of 64 PTC CB, 7 of 10 FVPTC CB, and 9 of 12 FLUS CB. All other cases were negative for TROP-2. TROP-2 showed a sensitivity of 95.31% and specificity of 89% for classic PTC in FNA CB. In TMA samples, TROP-2 stained 54 of 60 classic PTC cases and hence showed a high sensitivity and specificity. All BTN in CB and TMA were negative. We conclude that TROP-2 is a highly sensitive and specific IHC marker for identifying classic PTC. TROP-2 may play an important role in diagnosing classic PTC, especially in equivocal cases. This study also identifies a strong role for TROP-2 in separating PTC from BTN.

Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19

“…Studies, except one, demonstrated that TROP-2 was negative in neoplastic and non-neoplastic benign thyroid tissues [15,16,17]. Addati et al reported TROP-2 positivity in 4 non-neoplastic thyroid tissues and 2 cases of follicular adenoma [14].…”

“…TROP-2, which is expressed on normal levels in various normal tissues especially placenta, is related to tumor growth, tumor progression and the invasiveness of tumor cells [13]. Recently, there have been studies reporting that TROP-2 may be used in the differential diagnosis of follicular epithelial cell derived thyroid lesions [14,15,16,17].…”

Diagnostic utility of trophoblastic cell surface antigen 2 immunohistochemical expression in papillary thyroid carcinoma

“…16 Few recent studies have examined the role of TROP-2 in diagnosing PTC. 6,11,12,15 However, there was no agreement on the scoring system or its exact positive cut-off value, since all studies used different methods for IHC evaluation (automated or visual assessment). Also they used different quality of antibodies (mono-or polyclonal antibody).…”

“…Anti-Trop-2 monoclonal antibodies have been shown to kill uterine serous papillary carcinoma cells in vitro. 10,12 Recently, few studies have investigated the role of TROP-2 in diagnosing PTC and have reported that TROP-2 is a promising marker for identifying PTC. 12 These studies urged us to evaluate TROP-2 expression and its diagnostic utility on tissue histopathological specimens and cell block cytological sections of PTC cases as well as other thyroid nodules with follicular pattern including hyperplastic nodules, FA and follicular carcinoma.…”

Incorporation of CD40 ligand enhances the immunogenicity of tumor‑associated calcium signal transducer 2 virus‑like particles against lung cancer

“…The tumor-associated calcium signal transducer 2 (Trop-2) is a type-1 transmembrane protein. Although Trop-2 is overexpressed in a large variety of human epithelial carcinomas (1)(2)(3)(4)(5), its expression is minimal or restricted in normal tissues. Notably, elevated expression of Trop-2 is associated with more aggressive disease and poor prognosis in several cancer types (6)(7)(8).…”